New hope for leukemia patients: targeted drug plus chemo shows promise
NCT ID NCT06497062
First seen May 02, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests a new drug called sonrotoclax combined with strong chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combo can improve event-free survival and remission rates. Treatment is adjusted based on each patient's genetic risk and response, aiming for better control of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Conditions
Explore the condition pages connected to this study.